secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001823239-24-000028
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M
--------------------------------------------------------------------------------

- Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.
- Nucleic Acid Production revenue $58.8M in Q4, down 69% YoY; COVID CleanCap revenue fell $105M YoY.
- Full year 2023 revenue $288.9M (down 67% YoY); net loss $138.4M vs net income $490.7M.
- Introduced 2024 revenue guidance of $265M-$285M, below 2023 actual.
- Announced CleanCap patent awards in China/Canada, supply deal with FUJIFILM Toyama Chemical, and Cygnus-Dyadic partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/0001823239-24-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000028/mrvi-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001823239-24-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer